Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 1, 2012, Pages 117-121

  Horai, Y ^a   Miyamura, T ^a   Shimada, K ^a   Takahama, S ^a   Minami, R ^a   Yamamoto, M ^a   Suematsu, E ^a  

^a National Hospital   (Japan)

Author keywords

anti TNF blockers; choice of anti TNF blocker; interstitial lung disease; review

Indexed keywords

BUCILLAMINE; C REACTIVE PROTEIN; CARBOHYDRATE ANTIGEN; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ISONIAZID; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; SALAZOSULFAPYRIDINE; SIALYLATED CARBOHYDRATE ANTIGEN; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ABNORMAL RESPIRATORY SOUND; ADULT; AGED; ARTHRALGIA; ARTIFICIAL VENTILATION; ASPERGILLOSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL ARTICLE; COUGHING; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG WITHDRAWAL; ENDOTRACHEAL INTUBATION; FEMALE; HEART ATRIUM FIBRILLATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; HUMAN TISSUE; HYPOXEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INTENSIVE CARE; INTERSTITIAL LUNG DISEASE; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; OXYGEN SATURATION; PROTEIN BLOOD LEVEL; PSEUDOMEMBRANOUS COLITIS; RESPIRATORY FAILURE; REVIEW; RHEUMATOID ARTHRITIS; STEROID THERAPY; TUBERCULOSIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84856335082     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01234.x     Document Type: Review

References (14)

1. Katikireddi VS, Whittle SL, Hill CL,. Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. International Journal of Rheumatic Diseases, 2010; 13: 12-26.
2. Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis and Rheumatism, 2009; 61: 305-312.
3. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al, TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis and Rheumatism, 2006; 54: 1063-1074. (Pubitemid 43672919)
4. Peno-Green L, Lluberas G, Kingsley T, Brantley S,. Lung injury linked to etanercept therapy. Chest, 2002; 122: 1858-1860. (Pubitemid 35366106)
5. Yousem SA, Dacic S,. Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy. Modern Pathology, 2005; 18: 651-655. (Pubitemid 40676376)
6. Phillips K, Weinblatt M,. Granulomatous lung disease occurring during etanercept treatment. Arthritis and Rheumatism, 2005; 53: 618-620. (Pubitemid 41278929)
7. Lindsay K, Melsom R, Jacob BK, Mestry N,. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford), 2006; 45: 1048-1049. (Pubitemid 44283069)
8. Hagiwara K, Sato T, Takagi-Kobayashi S, Hasegawa S, Shigihara N, Akiyama O,. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. The Journal of Rheumatology, 2007; 34: 1151-1154. (Pubitemid 46774864)
9. Tournadre A, Ledoux-Eberst J, Poujol D, Dubost JJ, Ristori JM, Soubrier M.,. Exacerbation of interstitial lung disease during etanercept therapy: two cases. Joint Bone Spine, 2008; 75: 215-218. (Pubitemid 351418271)
10. Miyasaka N, Takeuchi T, Eguchi K,. Guidelines for the proper use of etanercept in Japan. Modern Rheumatology, 2006; 16: 63-67.
11. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. Journal of Rheumatology, 2009; 36: 898-906.
12. Kapanci Y, Desmouliere A, Pache JC, Redard M, Gabbiani G,. Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor alpha. American Journal of Respiratory and Critical Care Medicine, 1995; 152: 2163-2169.
13. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine, 2008; 178: 948-955.
14. Kuroki M, Noguchi Y, Shimono M, et al. Repression of bleomycin-induced pneumopathy by TNF. Journal of Immunology, 2003; 170: 567-574. (Pubitemid 36026184)